Which of the following is the most appropriate addition to Mr P's COPD treatment?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

Which of the following is the most appropriate addition to Mr P's COPD treatment?

Explanation:
Long-acting bronchodilators form the cornerstone of maintenance therapy in COPD, and a long-acting muscarinic antagonist like tiotropium provides sustained bronchodilation, reduces exacerbations, and improves symptoms. Its once-daily dosing also helps with adherence, making it a practical and effective addition when maintenance optimization is needed. Salbutamol would only address immediate relief, not ongoing control. Theophylline has a narrow therapeutic window and many interactions, making it a less favorable option. Roflumilast is reserved for a subset of patients with severe COPD and chronic bronchitis who have frequent exacerbations despite optimal inhaled therapy, not for general first-line addition.

Long-acting bronchodilators form the cornerstone of maintenance therapy in COPD, and a long-acting muscarinic antagonist like tiotropium provides sustained bronchodilation, reduces exacerbations, and improves symptoms. Its once-daily dosing also helps with adherence, making it a practical and effective addition when maintenance optimization is needed.

Salbutamol would only address immediate relief, not ongoing control. Theophylline has a narrow therapeutic window and many interactions, making it a less favorable option. Roflumilast is reserved for a subset of patients with severe COPD and chronic bronchitis who have frequent exacerbations despite optimal inhaled therapy, not for general first-line addition.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy